BioSpace News Archive

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS, and oncology/hematology, announced that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. for the Company’s CNS drugs with the indications of MDD and ADHD .

Hospital for Special Surgery, the world’s leading musculoskeletal health institution, has received support from Schmidt Futures to advance its research and development efforts in artificial intelligence and machine learning.

CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, announced the appointment of Edward J. Benz, M.D., to its Board of Directors.

The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have approved Kanna Health’s Investigational New Drug (IND) application and Clinical Trial Application (CTA), respectively, to start participant enrollment in a Phase 1 first-in-human clinical trial investigating the Safety and Pharmacokinetics of KH-001 Besylate (KH-001) in Healthy Male Subjects.

The US Food and Drug Administration (FDA) has granted over-the-counter marketing clearance for the ManaFlexx 2®, an Electrical Stimulation (EMS) device, from MANAMED®, LLC.

Scientists, clinicians, and others taking part in the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference learned the latest insights about C2N Diagnostics, LLC’s Precivity™ line of blood tests to facilitate earlier and more accurate diagnosis of Alzheimer’s disease pathology by healthcare providers.

Karuna Therapeutics, Inc. (NASDAQ: KRTX) today announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.

Rosalind Franklin University of Medicine and Science announces the appointment of molecular biologist Weihang “Valerie” Chai, PhD, as director of the Center for Genetic Diseases.

Protagonist Therapeutics, Inc. reported that on November 15, 2023, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters.

AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).